Table 1.
Randomized trials assessing adjuvant RT for prostate cancer.
| Trial, Year | n | Inclusion Criteria | Arms | Median Follow-Up (Years) | % of Patients with Salvage RT for BCR in the Observation Arm | Median PSA at Salvage RT (ng/mL) | 10 Year-bPFS | 10 Year-MFS | 10 Year-OS |
|---|---|---|---|---|---|---|---|---|---|
| SWOG 8794 (2009) | 431 | pT3 cN0 ± R1 | 60–64 Gy vs. observation | 12.6 | 33% | 0.75–1.0 | 60.7% vs. 47.4% (p < 0.005) | 71% vs. 61% (p = 0.04) * | 74% vs. 66% (p = 0.023) |
| EORTC 22911 (2012) | 1005 | pT2 pN0 R1 pT3 pN0 ± R1 |
60 Gy vs. observation | 10.6 | 43% | 1.7 | 60.6% vs. 41.1% (p < 0.001) * | 89.9% vs. 89% (ns) | 80.7% vs. 76.9% (ns) |
| ARO 96-02 (2014) | 388 | pT3 pN0 ± R1 undetectable PSA |
60 Gy vs. observation | 9.3 (adjuvant group), 9.4 (observation) | NR | NR | 56% vs. 35% (p = 0.005) * | 84.3% vs. 85.1% (ns) | 82% vs. 86% (ns) |
| FinnProstate Group (2019) | 250 | pT2 R1, pT3a | 66.6 Gy vs. observation | 9.3 (adjuvant group), 8.6 (observation) | 86% | 0.7 | 82% vs. 61% (p < 0.001) * | 98% vs. 96% (ns) | 92% vs. 87% (ns) |
Abbreviations: RT = radiation therapy, BCR = biochemical recurrence, bPFS = biochemical progression-free survival, MFS = metastasis-free survival, OS = overall survival, * indicates the primary endpoint of the trial, ns = no significance.